Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379285655> ?p ?o ?g. }
Showing items 1 to 78 of
78
with 100 items per page.
- W4379285655 endingPage "e13113" @default.
- W4379285655 startingPage "e13113" @default.
- W4379285655 abstract "e13113 Background: Breast cancer (BC) is the 2 nd most common cause of cancer related deaths in women. Antibody-drug conjugates are monoclonal antibodies conjugated to the cytotoxic payload and are directed towards cell surface proteins specific to tumor cells. This systematic review and meta-analysis aims to assess the efficacy of ADCs in breast cancer and comparison of different ADCs. Methods: A literature search was performed on PubMed, Embase, WOS, and clinicaltrials.gov with key words “breast neoplasms,” and “immunoconjugates” from the inception of data till 6/6/2022. Cochrane and PRISMA guidelines were followed to establish guidelines registered on Prospero (CRD42022329529). Out of 4,570 articles, seven randomized clinical trials (RCTs, N=5,302) were included. R programming language software with “meta” package was used for this meta-analysis. Results: In 7 RCTs (N=5,302), 4,834 patients had HER-2 positive disease while 468 patients were triple negative BC (TNBC). 1,486 patients had residual invasive disease while 3,816 patients had metastatic breast cancer (mBC). 3,389 patients were treated with ADC (235 with sacituzumab govitecan (saci-gov), 2,339 with trastuzumab emtansine (T-DM1) and 261 trastuzumab deruxtecan (T-der)), 2,105 patients were treated with chemotherapy regimens. In 4 RCTs on HER-2 patients (N=2,825), pooled HR of PFS and OS were 0.72 (95% CI=0.61-0.84, I 2 =71%) and 0.73 (95% CI=0.64-0.84, I 2 =20%), respectively, in favor of ADC. Risk of ORR was 1.48 (95% CI=0.84-2.60, I 2 =91%) in favor of ADC. In RCT on TNBC (N=468), HR of PFS and OS were 0.55 (95% CI=0.51-0.61) and 0.59 (95% CI=0.54-0.66), respectively, in favor of saci-gov (ADC). In RCT on HER-2 positive residual invasive breast cancer, HR of recurrence/death was 0.61 (95% CI=0.54-0.69) in favor of T-DM1. In an RCT by Cortes et al. (N=524) comparing two ADCs in HER-2 mBC, the HR of PFS and OS were 0.28 (95% CI= 0.22-0.37) and 0.55 (95% CI=0.36-0.86), respectively, in favor of T-der as compared to T-DM1. The RR of ORR and CR were 2.33 and 1.28, respectively, in favor of T-der. Conclusions: ADCs are significantly more effective than chemotherapy in patients with HER-2 positive mBC, HER-2 positive residually invasive BC, and metastatic TNBC in terms of improving survival and response rates. Among ADCs, T-der was significantly more effective than T-DM1 in patients with HER-2 positive mBC. More double blinded multicenter RCTs are needed to confirm these results." @default.
- W4379285655 created "2023-06-05" @default.
- W4379285655 creator A5003202406 @default.
- W4379285655 creator A5008253905 @default.
- W4379285655 creator A5024387685 @default.
- W4379285655 creator A5039006375 @default.
- W4379285655 creator A5040178199 @default.
- W4379285655 creator A5052186975 @default.
- W4379285655 creator A5078739501 @default.
- W4379285655 creator A5079886123 @default.
- W4379285655 creator A5086740295 @default.
- W4379285655 creator A5019549818 @default.
- W4379285655 date "2023-06-01" @default.
- W4379285655 modified "2023-09-25" @default.
- W4379285655 title "Efficacy of antibody-drug conjugates in breast cancer: A systematic review and meta-analysis of randomized clinical trials." @default.
- W4379285655 doi "https://doi.org/10.1200/jco.2023.41.16_suppl.e13113" @default.
- W4379285655 hasPublicationYear "2023" @default.
- W4379285655 type Work @default.
- W4379285655 citedByCount "0" @default.
- W4379285655 crossrefType "journal-article" @default.
- W4379285655 hasAuthorship W4379285655A5003202406 @default.
- W4379285655 hasAuthorship W4379285655A5008253905 @default.
- W4379285655 hasAuthorship W4379285655A5019549818 @default.
- W4379285655 hasAuthorship W4379285655A5024387685 @default.
- W4379285655 hasAuthorship W4379285655A5039006375 @default.
- W4379285655 hasAuthorship W4379285655A5040178199 @default.
- W4379285655 hasAuthorship W4379285655A5052186975 @default.
- W4379285655 hasAuthorship W4379285655A5078739501 @default.
- W4379285655 hasAuthorship W4379285655A5079886123 @default.
- W4379285655 hasAuthorship W4379285655A5086740295 @default.
- W4379285655 hasConcept C121608353 @default.
- W4379285655 hasConcept C126322002 @default.
- W4379285655 hasConcept C143998085 @default.
- W4379285655 hasConcept C159654299 @default.
- W4379285655 hasConcept C168563851 @default.
- W4379285655 hasConcept C203014093 @default.
- W4379285655 hasConcept C2775930923 @default.
- W4379285655 hasConcept C2777325958 @default.
- W4379285655 hasConcept C2778087150 @default.
- W4379285655 hasConcept C2779786085 @default.
- W4379285655 hasConcept C530470458 @default.
- W4379285655 hasConcept C542903549 @default.
- W4379285655 hasConcept C71924100 @default.
- W4379285655 hasConcept C95190672 @default.
- W4379285655 hasConceptScore W4379285655C121608353 @default.
- W4379285655 hasConceptScore W4379285655C126322002 @default.
- W4379285655 hasConceptScore W4379285655C143998085 @default.
- W4379285655 hasConceptScore W4379285655C159654299 @default.
- W4379285655 hasConceptScore W4379285655C168563851 @default.
- W4379285655 hasConceptScore W4379285655C203014093 @default.
- W4379285655 hasConceptScore W4379285655C2775930923 @default.
- W4379285655 hasConceptScore W4379285655C2777325958 @default.
- W4379285655 hasConceptScore W4379285655C2778087150 @default.
- W4379285655 hasConceptScore W4379285655C2779786085 @default.
- W4379285655 hasConceptScore W4379285655C530470458 @default.
- W4379285655 hasConceptScore W4379285655C542903549 @default.
- W4379285655 hasConceptScore W4379285655C71924100 @default.
- W4379285655 hasConceptScore W4379285655C95190672 @default.
- W4379285655 hasIssue "16_suppl" @default.
- W4379285655 hasLocation W43792856551 @default.
- W4379285655 hasOpenAccess W4379285655 @default.
- W4379285655 hasPrimaryLocation W43792856551 @default.
- W4379285655 hasRelatedWork W100456685 @default.
- W4379285655 hasRelatedWork W1472101725 @default.
- W4379285655 hasRelatedWork W2008699344 @default.
- W4379285655 hasRelatedWork W2031947447 @default.
- W4379285655 hasRelatedWork W2076131513 @default.
- W4379285655 hasRelatedWork W2129344486 @default.
- W4379285655 hasRelatedWork W2159967578 @default.
- W4379285655 hasRelatedWork W2939485277 @default.
- W4379285655 hasRelatedWork W3092625235 @default.
- W4379285655 hasRelatedWork W2182013281 @default.
- W4379285655 hasVolume "41" @default.
- W4379285655 isParatext "false" @default.
- W4379285655 isRetracted "false" @default.
- W4379285655 workType "article" @default.